122 results on '"Amit, Sharon"'
Search Results
2. Don't rash it! The clinical significance of positive Varicella zoster virus PCR in cerebrospinal fluid of patients with neurological symptoms
3. Potential value of a rapid syndromic multiplex PCR for the diagnosis of native and prosthetic joint infections: a real-world evidence study
4. Preparing for laboratory automation and consolidation—Establishing the validity of pediatric-like low-volume urine samples in boric-acid containing tubes
5. Public health-focused use of COVID-19 rapid antigen and PCR tests
6. 551 Early Onset Neonatal Sepsis: Prevalence Of Bacterial Pathogens and Maternal Risk Factors
7. Optimizing the Yield of In-and-Out Urinary Catheter Cultures by Applying a “Midstream-Like” Approach in Pediatric Patients
8. Corrigendum to 'Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up', Clinical Microbiology and Infection Volume 29, Issue 7, July 2023, Pages 918-923
9. Persistent SARS CoV2 Pneumonia in Patients Treated with Anti-CD20 Monoclonal Antibodies
10. Invasive Disease Due to Neisseria meningitidis: Surveillance and Trends in Israel Prior to and during the COVID-19 Pandemic
11. Phenotypic and genotypic analysis of antimicrobial resistance in Nocardia species
12. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
13. Real-Life Experience and Diagnostic Utility of the BioFire Joint Infection PCR Panel in Bone and Joint Infections: Analysis of a Prospective Validation Study
14. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
15. Trends in the Epidemiology of Non-Typhoidal Salmonellosis in Israel between 2010 and 2021
16. Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
17. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
18. An Outbreak of Coxsackievirus B Type 2 Acute Meningoencephalitis in Children, Israel, July–September 2022
19. The Use of Rapid COVID-19 Antigen Test in the Emergency Department as a Decision-Support Tool
20. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
21. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
22. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
23. Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years
24. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
25. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
26. The emergence of a multidrug resistant Salmonella Muenchen in Israel is associated with horizontal acquisition of the epidemic pESI plasmid
27. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
28. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
29. What Is Hiding in the Israeli Mediterranean Seawater and Beach Sand
30. Monkeypox DNA levels correlate with virus infectivity in clinical samples, Israel, 2022
31. Rapid Amplicon Nanopore Sequencing (RANS) for the Differential Diagnosis of Monkeypox Virus and Other Vesicle-Forming Pathogens
32. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up
33. Monkeypox DNA correlates with virus infectivity in clinical samples
34. Rapid Antigen Tests For Safe School Opening in the COVID-19 Pandemic Era
35. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
36. Durability of the immune response to a third BNT162b2 dose; five months follow-up
37. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
38. Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants
39. Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection
40. Real World Performance of SARS-CoV-2 Antigen Rapid Diagnostic Tests in Various Clinical Settings
41. Viral co-pathogens in COVID-19 acute respiratory syndrome – what did we learn from the first year of pandemic?
42. 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC
43. Persistent abdominal symptoms in returning travelers: Clinical and molecular findings
44. Syphilis reinfection among people living with HIV
45. Correlates of Protection of BNT162b2 Against COVID-19 Infection and Intensity of Symptomatic Disease; the Israeli COVID-19 Family Study (ICoFS)
46. Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
47. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
48. Immunoglobulin (Ig)A seropositivity against SARS-CoV-2 in healthcare workers in Israel, 4 April to 13 July 2020: an observational study
49. Predictors and outcomes of diabetic foot ulcer infection with ESBL-producing bacteria in a large tertiary center
50. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.